Goldvaser H, Katz Shroitman N, Ben-Aharon I, Purim O, Kundel Y, Shepshelovich D, Shochat T, Sulkes A, Brenner B. Octogenarian patients with colorectal cancer: Characterizing an emerging clinical entity. World J Gastroenterol 2017; 23(8): 1387-1396
Corresponding Author of This Article
Hadar Goldvaser, MD, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, 39 Jabotinski Street, Petach Tikva 4941492, Israel. firstname.lastname@example.org
Checklist of Responsibilities for the Scientific Editor of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
1Valid percentages. Missing data as follows: ethnicity (n = 8); 2nd malignancy (n = 1); family history of malignancy (n = 43); family history of CRC (n = 43); IBD (n = 5), polyps (n = 5); HNPCC/FAP (n = 14); smoking history (n = 16), performance status (n = 25);
2Polyps- diagnosis of polyps before or during CRC diagnosis;
3Performance status was determined according to the Eastern Cooperative Oncology Group score during the first encounter with the oncologist. CRC: Colorectal cancer; IBD: Inflammatory bowel disease; FAP: Familial adenomatous polyposis; HNPCC: Hereditary non-polyposis colorectal cancer; d/t: Due to.
1Valid percentages. Missing data as follows: adjuvant/neoadjuvant treatment (n = 4); no. of lymph nodes dissected (n = 20); type of chemotherapy (n = 7); No. of chemotherapy lines (n = 12); local intervention to a metastatic site (n = 4), hematological toxicity (n = 19); non-hematological toxicity (n = 19);
2Data regarding patients who presented with non-metastatic disease;
3Data regarding patients who presented with metastatic disease;
4Chemotherapy was given with or without a biological agent including bevacizumab, cetuximab or panitumumab;
5Local intervention to a metastatic site included: radiofrequency ablation, chemoembolization, intra-arterial chemotherapy, stereotactic body irradiation, and radiotherapy. LN: Lymph nodes; Tx: Treatment.
Table 4 Univariate and multivariate analyses of cancer specific survival and disease free survival
1Univariate and multivariate analysis for CSS were performed for patients with stage I-IV;
2Multivariate analysis was calculated for the entire follow-up period. The column of multivariate analysis depicts only factors that were included in the model;
3Univariate and multivariate analysis for DFS were performed for patients with stage I-III. DFS: Disease free survival; CRC: Colorectal cancer; CSS: Cancer specific survival; LVI: Lymphovascular invasion; NA: Not applicable; NOS: Not otherwise specified; Tx: Treatment; VVI: Venovascular invasion.
Citation: Goldvaser H, Katz Shroitman N, Ben-Aharon I, Purim O, Kundel Y, Shepshelovich D, Shochat T, Sulkes A, Brenner B. Octogenarian patients with colorectal cancer: Characterizing an emerging clinical entity. World J Gastroenterol 2017; 23(8): 1387-1396